Aztreonam-avibactam:an option against carbapenem-resistant Enterobacterales with emerging resistance  

作　　者：Shikai Wu Zhiyong Zong 

机构地区：[1]Center of Infectious Diseases,West China Hospital,Sichuan University,Chengdu 610041,China [2]Division of Infectious Diseases,State Key Laboratory of Biotherapy,Sichuan University,Chengdu 610041,China [3]Center for Pathogen Research,West China Hospital,Sichuan University,Chengdu 610041,China

出　　处：《Precision Clinical Medicine》2022年第4期256-258,共3页精准临床医学（英文）

基　　金：supported by the National Natural Science Foundation of China(Grants No.82172309 and 81861138055);the 1.3.5 Project for Disciplines of Excellence from West China Hospital of Sichuan University(Grant No.ZYGD22001).

摘　　要：Dear Editor,The Enterobacterales are an order of Gram-negative bacteria comprising a few major human pathogens such as Escherichia coli and Klebsiella pneumoniae.However,carbapenem-resistant Enterobacterales(CRE)has risen as an urgent threat for human health,leading to high mortality with very limited antimicrobial options.The main mechanism mediating resistance to βlactams including carbapenems in the Enterobacterales is production of β-lactamases,which are two categories of enzymes capable of hydrolyzing β-lactams:serine β-lactamases and metallo β-lactamases(MBLs).

关 键 词：PENEM URGENT risen 

分 类 号：R978.1[医药卫生—药品] R378[医药卫生—药学]